Skip to main content
NANOSONICS LIMITED logo

NANOSONICS LIMITED — Investor Relations & Filings

Ticker · NAN ISIN · AU000000NAN9 LEI · 549300XUBCM70BRANN81 ASX Manufacturing
Open in API
Filings indexed 1,048 across all filing types
Latest filing 2025-03-23 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NAN

About NANOSONICS LIMITED

https://www.nanosonics.com.au

Nanosonics Limited is a medical technology company specializing in the development and commercialization of infection prevention solutions. The company's flagship product, the trophon system, provides automated high-level disinfection (HLD) for ultrasound probes. Utilizing a proprietary hydrogen peroxide mist technology, the trophon device ensures consistent and effective disinfection of both the probe handle and shaft, addressing the risks of cross-contamination in clinical settings. The system is designed to integrate into diagnostic workflows, offering a faster and more environmentally sustainable alternative to traditional manual chemical soaking methods. Nanosonics continues to expand its portfolio with digital traceability tools and audit-ready reporting software to enhance compliance and patient safety across global healthcare facilities.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - NAN 7 pages 19.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and compliance with listing rules. This type of document is a formal announcement related to capital changes, specifically the quotation of new securities. It is not a financial report, earnings release, or management discussion. It fits the category of announcements regarding new share issues or capital changes.
2025-03-23 English
Nanosonics Receives FDA De Novo Clearance for CORIS 1
Regulatory Filings Classification · 95% confidence The document is a company announcement from Nanosonics Limited regarding FDA De Novo clearance for a new product, CORIS®. It discusses the product's features, regulatory approvals, and commercial launch plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is an update on regulatory approval and commercialization progress rather than a financial report or detailed investor presentation. It is also not a report publication announcement since it does not mention the release or attachment of a report. The content fits best under a general regulatory announcement category, as it informs the market about a significant regulatory milestone and future plans without financial data or voting results.
2025-03-19 English
Change of Director's Interest Notice 2 pages 176.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and the value of the transaction. The document is 3397 characters long, which is relatively short and focused solely on insider share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). There is no indication that this is a full financial report, regulatory filing, or announcement of a report. Therefore, the correct classification is DIRS.
2025-03-13 English
Application for quotation of securities - NAN 7 pages 19.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and other listing rule compliance information. This type of document is a formal announcement related to capital changes, specifically the quotation of new securities. It is not a financial report, earnings release, or management discussion. It fits the category of announcements regarding new share issues or capital changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or a report publication announcement.
2025-03-12 English
Update - Notification regarding unquoted securities - NAN 6 pages 19.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities (performance rights) under an employee equity plan. It includes specifics about the securities issued, dates, and key management personnel involved. This type of announcement relates to changes in the company's capital structure, specifically the issuance of securities. It is not a full financial report, earnings release, or management discussion. It is an update to a previous announcement about securities issuance. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a substantive announcement rather than a brief notice or regulatory filing.
2025-03-11 English
Change of Director's Interest Notice 4 pages 295.8KB
Director's Dealing Classification · 100% confidence The document is titled 'APPENDIX 3Y Change of Director’s Interest Notice' and details changes in securities held by a company director, including performance rights and shares. It references ASX Listing Rule 3.19A.2, which pertains to disclosure of director's interests. The content is focused on reporting a director's personal share transactions and interests, not on financial results, management changes, or other report types. The document length is 6413 characters, sufficient for a detailed notice but it is clearly a regulatory disclosure of insider transactions. Therefore, the document fits the category of Director's Dealing (DIRS).
2025-03-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.